西妥昔单抗再挑战方案后线治疗晚期结直肠癌的研究进展

Research Progress on the Rechallenge with Cetuximab Regimen as Post-Line Therapy for Advanced Colorectal Cancer

结直肠癌是常见的恶性肿瘤之一。目前表皮生长因子受体单克隆抗体联合化疗是RAS野生型左半晚期结直肠癌患者一线治疗的标准方案。西妥昔单抗是抗EGFR单抗的常见代表药物之一。近年来,研究发现既往接受含西妥昔单抗方案治疗后进展的一部分晚期结直肠癌患者在经历无西妥昔单抗治疗一段时间后可能恢复对西妥昔单抗的敏感性。因此西妥昔单抗再挑战治疗可延长晚期结直肠癌患者的治疗生存期。全文就西妥昔单抗治疗结直肠癌的治疗现状及再挑战治疗的研究进展进行综述。

Colorectal cancer is one of the most common malignant tumors.The combination of chemotherapy with anti-epidemal growth factor receptor(EGFR)monoclonal antibodies has become the standard first-line treatment for RAS wild-type left-sided metastatic colorectal cancer(mCRC)patients.Cetuximab is a commonly used anti-EGFR monoclonal antibody.Recent studies have found that some patients with metastatic colorectal cancer who have progressed after treatment with regimens containing cetuximab may regain sensitivity to it after a period of cetuximab withdraw.Therefore,the rechallenge therapy with cetuximab may prolong the survival of patients with advanced colorectal cancer.This paper reviews the current status of cetuximab in the treatment of colorectal cancer and the research progress of its rechallenge therapy.